Combination Drug Therapy for the Management of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In AD research, priorities concern the development of disease-modifying therapeutic agents to be used in the early phases of AD and the optimization of the symptomatic treatments predominantly dedicated to the more advanced AD stages. Until now, available therapeutic agents for AD treatment only provide symptomatic treatment. Since AD pathogenesis is multifactorial, use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression. It has been demonstrated through numerous studies, that the clinical efficacy of combination therapy (CT) is higher than that of monotherapy. In case of AD, CT is more effective, mostly when started early, at slowing the rate of cognitive impairment. In this review, we have covered the major studies regarding CT to combat AD pathogenesis. Moreover, we have also highlighted the safety, tolerability, and efficacy of CT in the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the combination use of appropriate cholinesterase inhibitors, such as donepezil (4) and galantamine (6), or the combination of cholinesterase inhibitors with other neurologic drugs, metal chelators, or antioxidants, may yield surprising effects in the management of cholinergic drugs in AD, including efficacy, tolerability, and safety.402,408”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [402]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
Cited by
Items 201–218 of 218
Oncology drug repurposing as a blueprint for Alzheimer's therapy
Das, V., & Hajdúch, M. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70231 · Cited by 2
Sorokina, K. N., Толстикова, Т. Г., Usov, V. Y., & Тулупов, А. А. (2026) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20260102
Wu, J.-Y., Zhang, J., Xu, S., Qian, S.-Y., Zha, Z., Hu, J., Yang, J.-L., Zhang, F., & Zheng, G. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s567313
Vijayalakshmi, P., Alex, A. M., Muthupandian, S., Desai, D., Jayaprakashvel, M., Singh, S. K., & Selvaraj, C. (2026) · International review of neurobiology · doi:10.1016/bs.irn.2026.02.003
Length-Dependent Aβ-Gelsolin Interactions Regulate Amyloid Aggregation in Alzheimer’s Disease
Ma, L., Zheng, Y., Huang, J., & Yang, X. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.5c06477
Adhikary, S., Rajak, P., Bhattacharya, S., & Ganguly, A. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898813062126060011
Recent Advances in Drug Development for the Management of Alzheimer’s Disease
Upadhyay, A., Singh, A. K., Jayaswal, N., Jaiswal, P., Singh, S. N., & Tewari, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010014
Tiny Titans, big promise: Nanotechnology and microRNA in the fight against Alzheimer’s disease
Nakum, B., Vejpara, D., Faldu, K. G., Soni, R., & Shah, J. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103149
Ugwah-Oguejiofor, C. J., Okechukwu, P. N., Mathias, S. N., Ofokansi, M. N., & Janakiraman, A. K. (2026) · Studies in natural products chemistry · doi:10.1016/b978-0-443-49144-3.00007-1
Kim, D. H., Jeong, H., Lim, H. K., Ahn, S. M., & Song, M. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261450638
Liu, X., Zhang, Y., Zhang, X., Chang, T., Zhao, Z., Zhang, Y., Li, Z., Li, Z., Yang, X., & Lu, M. (2026) · Aging & Mental Health · doi:10.1080/13607863.2026.2678989 · Cited by 1
Unveiling the Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Karati, D., Meur, S., Sen, P., Mukherjee, S., & Ghosh, P. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010004
Pal, T., Mukherjee, S., Karati, D., Pahari, N., Hossain, C. M., & Naskar, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010017
Generative AI-Assisted Molecular Design of AChEIs
Agarwal, D., Gautam, R. K., Gupta, V., Chaurasia, V., Sharma, A., Varma, T., Modi, G. P., Guchhait, S. K., & Garg, P. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c02233
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“In addition, it is more convenient than the once-daily rivastigmine patch (140, 141) (Figure 4).”
Aducanumab: a decade in the making and a hopeful tactic for addressing alzheimer’s
Gollapudi, R., Medabalimi, V., Nallam, S. M., Kolusu, A. S., Kalidindi, V. R., & Samudrala, P. K. (2026) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902026e24625
BindingDB (2022) · UC San Diego · doi:10.7270/q2222zkw
Metadata
- Authors
- Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M.
- Affiliations
- BRAC University (BD)
- Southeast University (BD)
- Centre National de la Recherche Scientifique (FR)
- King Abdulaziz University (SA)
- Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, India
- Princess Nourah bint Abdulrahman University (SA)
- Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
- Corresponding author
- Uddin, Md. Sahab
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-05
- Volume
- 21
- Issue
- 9
- Pages
- 3272
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7246721
- OpenAlex
- W3022707404
- Cited by
- 217
- References
- 135
- Citations by year
- 2026: 26 · 2025: 43 · 2024: 34 · 2023: 30 · 2022: 40 · 2021: 27 · 2020: 17
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Griffith Research Online (submittedVersion, cc-by)
- Funders
- Princess Nourah Bint Abdulrahman University
- Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy, multimodal therapy, disease-modifying therapy, symptomatic treatment, early intervention, cognitive impairment, drug safety and tolerability, drug efficacy
- MeSH terms
- Alzheimer Disease, Animals, Cholinesterase Inhibitors, Clinical Trials as Topic, Disease Susceptibility, Drug Therapy, Combination, Galantamine, Humans, Memantine, Dopamine Agents, Biomarkers, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.